Drug Trial Radar · NCT02301091
Combine TACE and RFA Versus TACE Alone for HCC With PVTT
Last checked: Nov 20, 2026Latest source record: Apr 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
240
Planned (sponsor's estimate)
Start
Oct 2014
Primary completion
Oct 2018
Study completion Oct 2019
Sponsor
- Lead sponsor
- Ming ZhaoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 25, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether combined radiofrequency ablation and transcatheter chemoembolization (TACE) result in better survival outcomes than TACE alone in patients with HCC and portal vein tumor thrombus.
Conditions
- Hepatocellular Carcinoma
Interventions
TACEProcedure
TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
RFAProcedure
For RFA, we used two commercially available system (Cool-Tip, Valleylab,USA) and (Octopus RF Systema,Starmed,Korea)with needle electrode with a 17-gauge internally cooled electrode.
pirarubicin,mitomycin and lobaplatinDrug
They were cytotoxic drugs used in the TACE procedure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival ratesTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center,
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.